Your browser is no longer supported. Please, upgrade your browser.
SOLY Soliton, Inc. daily Stock Chart
Soliton, Inc.
Index- P/E- EPS (ttm)-0.71 Insider Own5.70% Shs Outstand13.80M Perf Week-10.67%
Market Cap164.08M Forward P/E- EPS next Y- Insider Trans- Shs Float13.79M Perf Month61.77%
Income-10.60M PEG- EPS next Q- Inst Own- Short Float0.11% Perf Quarter-
Sales- P/S- EPS this Y-29.10% Inst Trans- Short Ratio0.07 Perf Half Y-
Book/sh-9.27 P/B- EPS next Y- ROA-879.50% Target Price- Perf Year-
Cash/sh0.01 P/C1640.82 EPS next 5Y- ROE66.40% 52W Range4.12 - 15.00 Perf YTD144.15%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-20.73% Beta-
Dividend %- Quick Ratio0.00 Sales past 5Y- Gross Margin- 52W Low188.59% ATR1.36
Employees7 Current Ratio0.00 Sales Q/Q- Oper. Margin- RSI (14)59.67 Volatility16.34% 13.15%
OptionableNo Debt/Eq- EPS Q/Q-43.70% Profit Margin- Rel Volume1.77 Prev Close13.21
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume205.39K Price11.89
Recom- SMA2016.80% SMA5056.46% SMA20056.46% Volume363,906 Change-9.99%
Apr-18-19 08:00AM  Soliton to be Featured on Yahoo Finance's 'The First Trade' Show on May 13, 2019 to Discuss Cellulite Trial Results PR Newswire -9.99%
Apr-15-19 08:00AM  Soliton Announces Cellulite Trial Results to be Presented at National Aesthetics Conference on May 11, 2019 PR Newswire +14.55%
Apr-09-19 08:00AM  Soliton Completes Cellulite Clinical Trials PR Newswire
Apr-04-19 08:00AM  Soliton Receives European Patent for Acoustic Shockwave Technology PR Newswire +11.11%
Apr-01-19 08:00AM  Soliton Initiated Clinical Trials for Treatment of Cellulite in Humans PR Newswire +10.74%
Mar-27-19 08:00AM  Soliton Receives FDA Acceptance for 510(k) Application PR Newswire
Mar-21-19 08:00AM  Soliton Files 510(k) with FDA for its Rapid Acoustic Pulse Device PR Newswire +8.16%
Mar-19-19 08:00AM  Soliton Completes Clinical Trials for Initial FDA Filing for Tattoo Indication PR Newswire +17.55%
Mar-18-19 08:00AM  Soliton to Present at Oppenheimer 29th Annual Healthcare Conference on March 20, 2019 PR Newswire
Mar-14-19 08:00AM  Soliton Partners with Sanmina, a Global Medical Device Manufacturer ACCESSWIRE +10.00%
Mar-12-19 08:00AM  Soliton to Ring the Nasdaq Stock Market Closing Bell on March 19, 2019 ACCESSWIRE
Mar-08-19 08:00AM  Soliton's RAP Device Received Institutional Review Board Approval of Non-Significant Risk Designation ACCESSWIRE
Mar-04-19 07:00AM  Soliton Receives FDA Approval for Small Business Designation ACCESSWIRE
Feb-28-19 07:00AM  Soliton Discusses Rapid Acoustic Pulse Technology for Treatment of Cellulite GlobeNewswire +6.85%
Feb-26-19 07:30AM  Soliton Receives Additional Patent for Breakthrough Acoustic Shockwave Technology GlobeNewswire
Feb-19-19 12:03PM  Soliton, Inc. Completes IPO and Begins Trading on Nasdaq Under Ticker Symbol SOLY GlobeNewswire
Soliton, Inc., an early stage medical device company, focuses on developing and commercializing products using a proprietary rapid acoustic pulse technology platform. It offers a device for the removal of tattoos. The company was founded in 2012 and is headquartered in Houston, Texas.